Clinical Trial Detail

NCT ID NCT02768558
Title Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors RTOG Foundation, Inc.
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Etoposide

Cisplatin + Etoposide + Nivolumab

Age Groups: adult senior

No variant requirements are available.